Rexnord Corp (RXN) 21.83 $RXN Rexnord to Participate in

New Post Public Reply Private Reply Replies (0) Message Board

Sep 6, 2016 at 9:07 PM

Rexnord Corp (RXN) 21.83 $RXN

Rexnord to Participate in Vertical Research Partners 2016 Industrials Conference
BusinessWire - Wed Aug 24, 10:00AM CDT
Rexnord Corporation (NYSE: RXN) today announced that it will participate in the Vertical Research Partners 2016 Industrials Conference at the Water's Edge Resort and Spa in Westbrook, CT on September 8, 2016, starting at 8:00 a.m. Eastern.
RXN: 21.83 (-0.15)

Rexnord (RXN) Beats Q1 Earnings & Revenues; Keeps View
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 6:46AM CDT
Rexnord Corporation's (RXN) adjusted earnings of 35 cents per share for first-quarter fiscal 2017 (ended Jun 30, 2016) surpassed the Zacks Consensus Estimate of 30 cents, while grew 9.4% year over year.
SWK: 122.87 (-0.94), FELE: 38.64 (-0.31), RXN: 21.83 (-0.15), AOS: 95.78 (-1.20)

Rexnord Reports Q1 FY2017 Financial Results
BusinessWire - Mon Aug 01, 3:31PM CDT
Rexnord Corporation (NYSE:RXN):
RXN: 21.83 (-0.15)

Industrial Stocks' Earnings to Watch on Aug 1: RXN, SNHY
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 6:17AM CDT
What's in Store for 2 Industrial Stocks, RXN and SNHY, in Apr-Jun 2016 quarter?
SNHY: 30.55 (-0.48), RXN: 21.83 (-0.15)

Rexnord's Long-Term Potential Solid, Runs Near-Term Risks
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 6:11AM CDT
We issued an updated research report on Rexnord Corporation (RXN) on Jun 24, 2016.
ETN: 66.62 (-0.92), FLOW: 29.85 (-0.19), RXN: 21.83 (-0.15), ENS: 69.71 (-1.60)

Rexnord to Participate in 2016 KeyBanc Capital Markets Industrial, Automotive & Transportation Conference
BusinessWire - Thu May 26, 11:36AM CDT
Rexnord Corporation (NYSE: RXN) today announced that it will participate in the KeyBanc Capital Markets Industrial, Automotive & Transportation Conference at the InterContinental Hotel in Boston on June 2, 2016, starting at 8:00 a.m. EDT.
RXN: 21.83 (-0.15)

Should Rexnord Corporation (RXN) Be in Your Portfolio Now?
Zacks Equity Research - Zacks Investment Research - Tue May 24, 9:24AM CDT
On May 23, 2016, Zacks Investment Research downgraded Rexnord Corporation (RXN) to a Zacks Rank #3 (Hold) from a Zacks Rank #2 (Buy).
ETN: 66.62 (-0.92), ESE: 46.06 (+0.09), RXN: 21.83 (-0.15), POWL: 39.58 (-0.81)

Rexnord (RXN) Beats Q4 Earnings, Down Y/Y; Revenues Lag
Zacks Equity Research - Zacks Investment Research - Thu May 19, 5:50AM CDT
Rexnord Corporation's (RXN) adjusted earnings of 37 cents per share for fourth-quarter fiscal 2016 (ended Mar 31, 2016) surpassed the Zacks Consensus Estimate of 36 cents but declined 43.1% year over year.
ETN: 66.62 (-0.92), FLOW: 29.85 (-0.19), ESE: 46.06 (+0.09), RXN: 21.83 (-0.15)

Rexnord to Acquire Cambridge International Holdings Corp.
BusinessWire - Wed May 18, 9:47PM CDT
Rexnord (NYSE: RXN) announced today that it has entered into a definitive agreement to acquire Cambridge International Holdings Corp. for an estimated total transaction value of $210 million. Subject to customary closing conditions, the transaction is expected to close in the next 30 days.
RXN: 21.83 (-0.15)

Rexnord Corporation Reports Fourth Quarter and Full Fiscal Year 2016 Results
BusinessWire - Wed May 18, 7:42PM CDT
Rexnord Corporation (NYSE:RXN):
RXN: 21.83 (-0.15)

5 Industrial Stocks to Buy as Output Revs Up
Zacks Equity Research - Zacks Investment Research - Wed May 18, 9:53AM CDT
Industrial production in the U.S. climbed at the fastest pace in more than a year in April.
RXN: 21.83 (-0.15), CMCO: 17.88 (+0.04), AIMC: 28.34 (-0.38), POWL: 39.58 (-0.81), UFI: 26.61 (+0.03)

Rexnord Schedules Q4 FY2016 Earnings Release and Investor Conference Call
BusinessWire - Mon May 02, 10:00AM CDT
Rexnord Corporation (NYSE: RXN) will hold a conference call and webcast presentation on Thursday, May 19, 2016 at 7:00 a.m. Central Time to discuss its fourth quarter fiscal year 2016 financial results, provide a general business update and respond to investor questions. Rexnord President and CEO Todd Adams and Senior Vice President and CFO Mark Peterson will co-host the call and webcast.
RXN: 21.83 (-0.15)

Rexnord (RXN) to Exit RHP Product Line, Reviews '16 Outlook
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 6:14PM CDT
Rexnord Corporation (RXN) recently announced its decision to exit its non-strategic RHF product line. The company also reviewed its guidance for fourth-quarter and fiscal year 2016.
PPSI: 5.61 (+0.02), RBC: 61.11 (-0.79), EMR: 52.56 (-0.35), RXN: 21.83 (-0.15)

A.O. Smith (AOS) Q1 Earnings Top, Revenues Miss Estimates
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 9:17AM CDT
A.O. Smith Corp. (AOS) continued with its earnings streak in first-quarter 2016, with earnings per share of 83 cents surpassing the Zacks Consensus Estimate of 77 cents by 7.8%.
RBC: 61.11 (-0.79), EMR: 52.56 (-0.35), RXN: 21.83 (-0.15), AOS: 95.78 (-1.20)

Rexnord Announces Product Line Exit and Previews Key Financial Metrics for the Fourth Quarter and Fiscal Year 2016
BusinessWire - Tue Apr 26, 7:26AM CDT
Rexnord Corporation (NYSE: RXN) is announcing its decision to exit a product line in its Water Management platform and the contribution of this product line to consolidated operating results in Rexnord's fiscal year 2016 fourth quarter and full year. Rexnord is also previewing its expectations for certain key financial metrics in its fourth fiscal quarter of 2016. Separately, Rexnord is announcing the planned dates for its fourth quarter and full-year earnings release and subsequent investor conference call.
RXN: 21.83 (-0.15)

Rexnord Beats Q3 Earnings, Lags Revenues; Cuts FY16 View
Zacks Equity Research - Zacks Investment Research - Thu Feb 04, 11:30AM CST
Rexnord Corporation's (RXN) adjusted earnings of 38 cents per share for third-quarter fiscal 2016 (ended Dec 31, 2015) surpassed the Zacks Consensus Estimate of 37 cents, while coming at par with the year-ago tally.
RXN: 21.83 (-0.15), MTW: 4.93 (+0.06), ASTE: 59.23 (+0.36)

Rexnord tops 3Q profit forecasts
Automated Insights - Tue Feb 02, 3:43PM CST
MILWAUKEE (AP) _ Rexnord Corp. (RXN) on Tuesday reported fiscal third-quarter earnings of $24.4 million.
RXN: 21.83 (-0.15)

REPEAT/Gabelli & Company's 26th Annual Pump, Valve & Water Systems Symposium
BusinessWire - Wed Jan 27, 6:00AM CST
Gabelli & Company will host its 26th Annual Pump, Valve & Water Systems Symposium on February 25, 2016 in New York City. This research meeting will feature presentations, fireside chats, and one-on-one meetings with senior management of several leading industrial companies, with an emphasis on industry dynamics, new technologies, and company fundamentals.
AC: 34.03 (-0.13), WTS: 65.22 (-0.68), IEX: 93.55 (-0.48), XYL: 50.97 (+0.05), PUR.TO: 6.15 (+0.10), AME: 48.92 (-0.23), GGG: 74.41 (-0.66), ITT: 36.28 (-0.47), BMI: 66.33 (-0.13), GBL: 30.72 (-0.07), FLS: 48.09 (-0.68), CR: 64.76 (-0.40), RXN: 21.83 (-0.15), TWIN: 11.97 (-0.63), MWA: 12.19 (unch), CIR: 58.80 (-1.26)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Quantum Space Joins $185M NASA Lunar Transport Deal

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Intelligent Communication Forum Eyes Global Ecosystem Shift

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Webull Faces Class Action Suit: Key Deadlines Loom

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Gildan's Crisis: Investors Face Losses Amid Lawsuit

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

MWC26 Doha: Bridging Standards for MENA's Future

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

D-Wave's Legal Trouble: Securities Fraud Suit Looms

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Allergan Aesthetics Study Shows Rising Patient Satisfaction

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Amplifon Data Breach Spurs Legal Scrutiny for Millions

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Novo's Semaglutide Shows Promise in MASH Study

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...